Revvity Q1 Results Beat Market; Backs FY25 Earnings View, Lifts Revenue Forecast; Stock Up

PerkinElmer

160.19 CHF 21.45%

• Charts
• News
• Analysen

Kaufen Verkaufen

(RTTNews) - Biotechnology company Revvity, Inc. (RVTY), while reporting higher first-quarter results above market estimates, on Monday reaffirmed its fiscal 2025 adjusted earnings forecast and raised total revenue outlook.

In pre-market activity on the NYSE, Revvity shares were gaining around 4.7 percent to trade at $98.73.

For the full year 2025, the company continues to expect adjusted earnings in a range of $4.90 to $5.00 per share.

Revenue is now expected in a range of $2.83 billion to $2.87 billion, higher than previously expected $2.80 billion and $2.85 billion, to reflect recent changes in foreign currency.

The company further reaffirmed its organic growth guidance of 3 percent to 5 percent.

On average, analysts polled expect the company to report earnings of $4.94 per share on revenues of $2.83 billion for the year. Analysts' estimates typically exclude special items.

In its first quarter, the company's net income climbed to $42.24 million or $0.35 per share from last year's $26.01 million or $0.21 per share.

Income from continuing operations was $41.67 million or $0.35 per share, up from $28.70 million or $0.23 per share a year ago.

Adjusted earnings per share from continuing operations for the quarter was $1.01, compared to $0.98 in the same period a year ago.

Revenue for the quarter was $664.76 million, as compared to $649.92 million in the same period a year ago.

The Street was looking for earnings of $0.95 per share on revenues of $661.66 million for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.